| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11398306 | EYENOVIA | Ophthalmic drug delivery |
Jul, 2031
(7 years from now) | |
| US10839960 | EYENOVIA | Ophthalmic drug delivery |
Jul, 2031
(7 years from now) | |
| US11839487 | EYENOVIA | Ophthalmic drug delivery |
Jul, 2031
(7 years from now) | |
Mydcombi is owned by Eyenovia.
Mydcombi contains Phenylephrine Hydrochloride; Tropicamide.
Mydcombi has a total of 3 drug patents out of which 0 drug patents have expired.
Mydcombi was authorised for market use on 05 May, 2023.
Mydcombi is available in spray, metered;ophthalmic dosage forms.
Mydcombi can be used as method of administering an effective dose of tropicamide and phenylephrine hydrochloride to an eye.
The generics of Mydcombi are possible to be released after 15 July, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2026 |
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE ingredient
Market Authorisation Date: 05 May, 2023
Treatment: Method of administering an effective dose of tropicamide and phenylephrine hydrochloride to an eye
Dosage: SPRAY, METERED;OPHTHALMIC
MYDCOMBI family patents
